Novel Enterococcus faecium P2 as a probiotic for mitigating Clostridioides difficile infection.

Clostridioides difficile (C. difficile) is a well-recognized pathogen responsible for severe intestinal disorders, including pseudomembranous colitis and toxic megacolon. Probiotics have shown considerable promise in the prevention and management of gastrointestinal diseases. In this study, we isolated Enterococcus faecium (E. faecium) P2 from the feces of a healthy child and evaluated its probiotic efficacy against C. difficile infection (CDI) using a mouse model. In vitro assessments demonstrated that E. faecium P2 exhibits high safety, tolerates gastrointestinal stressors, forms robust biofilms, and inhibits both the growth and biofilm formation of C. difficile. In vivo, prophylactic administration of E. faecium P2 prior to CDI onset significantly alleviated intestinal damage, as evidenced by reduced average total clinical scores and lower mortality rates. Furthermore, E. faecium P2 upregulated the expression of intestinal mucosa-associated proteins, including MUC-2 and the tight junction proteins ZO-1 and Claudin-1, indicating a protective effect on the intestinal barrier. E. faecium P2 also modulated the inflammatory response by decreasing pro-inflammatory factors and increasing the anti-inflammatory cytokine IL-10. Fecal microbiota analysis revealed that E. faecium P2 helps restore the microbial balance disrupted by CDI. Collectively, these findings highlight the potential of E. faecium P2 as a probiotic candidate for the prevention of CDI.

• Publication year

  2025

• Venue

  Microbial Pathogenesis

• Publication date

  2025-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.micpath.2025.108028PMID 40934987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial

  2025cited by this paper
• The Impact of Enterococcus spp. in the Immunocompromised Host: A Comprehensive Review

  2024cited by this paper
• Anti-biofilm properties of laser-synthesized, ultrapure silver–gold-alloy nanoparticles against Staphylococcus aureus

  2024cited by this paper
• Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus acidophilus C4

  2023cited by this paper
• An epidemiological surveillance study (2021–2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China

  2023cited by this paper
• Anti-inflammatory effect of Lactiplantibacillus plantarum T1 cell-free supernatants through suppression of oxidative stress and NF-κB- and MAPK-signaling pathways

  2023cited by this paper
• Therapeutic and prophylactic effects of oral administration of probiotic Enterococcus faecium Smr18 in Salmonella enterica-infected mice

  2023cited by this paper
• Modulation of Lactobacillus rhamnosus GG on the gut microbiota and metabolism in mice with Clostridioides difficile infection.

  2022cited by this paper
• Distinction between Enterococcus faecium and Enterococcus lactis by a gluP PCR-Based Assay for Accurate Identification and Diagnostics

  2022cited by this paper
• Enterococci enhance Clostridioides difficile pathogenesis

  2022cited by this paper
• Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model

  2022cited by this paper
• Microbiota-based markers predictive of development of Clostridioides difficile infection

  2021cited by this paper
• Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics

  2021cited by this paper
• The Many Faces of Enterococcus spp.—Commensal, Probiotic and Opportunistic Pathogen

  2021cited by this paper
• Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection

  2021cited by this paper
• Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With Enterococcus faecium SF68

  2020cited by this paper
• Enterococcus faecalis Isolated From Infant Feces Inhibits Toxigenic Clostridioides (Clostridium) difficile

  2020cited by this paper
• A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis

  2020cited by this paper
• Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

  2020cited by this paper
• Drosophila Histone Demethylase KDM5 Regulates Social Behavior through Immune Control and Gut Microbiota Maintenance.

  2019cited by this paper
• Probiotic Activity of Enterococcus faecium and Lactococcus lactis Isolated from Thai Fermented Sausages and Their Protective Effect Against Clostridium difficile

  2019cited by this paper
• Enterococci: Between Emerging Pathogens and Potential Probiotics

  2019cited by this paper
• Isolation and Characterization of Lactobacillus spp. from Kefir Samples in Malaysia

  2019cited by this paper
• Non-antibiotic therapy for Clostridioides difficile infection: a review

  2019cited by this paper
• Anti-biofilm Properties of the Fecal Probiotic Lactobacilli Against Vibrio spp.

  2018cited by this paper
• Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics.

  2018cited by this paper
• Probiotics for prevention of Clostridium difficile infection

  2018cited by this paper
• Clostridioides difficile Infection

  2018cited by this paper
• Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

  2018cited by this paper
• The role of the microbiota in infectious diseases

  2018cited by this paper
• Inhibition of Clostridium difficile in Mice Using a Mixture of Potential Probiotic Strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: Novel Candidates to Control C. difficile Infection (CDI)

  2017cited by this paper
• Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing

  2017cited by this paper
• A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.

  2017cited by this paper
• Clostridium difficile infection

  2016cited by this paper
• Frizzled are colonic epithelial receptors for Clostridium difficile toxin B

  2016cited by this paper
• Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study

  2016cited by this paper
• Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission

  2014cited by this paper
• Aggregation and adhesion properties of 22 Lactobacillus strains.

  2013cited by this paper
• The rise of the Enterococcus: beyond vancomycin resistance

  2012cited by this paper
• Current Status of Clostridium difficile Infection Epidemiology

  2012cited by this paper
• In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy

  2012cited by this paper
• Enterococci as probiotics and their implications in food safety.

  2011cited by this paper
• Biology of Clostridium difficile: implications for epidemiology and diagnosis.

  2011cited by this paper
• The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea.

  2009cited by this paper
• Auto-aggregation and Co-aggregation ability in bifidobacteria and clostridia

  2008cited by this paper
• Probiotic Strains and Their Combination Inhibit In Vitro Adhesion of Pathogens to Pig Intestinal Mucosa

  2007cited by this paper
• Evaluation of primers and PCR conditions for the analysis of 16S rRNA genes from a natural environment.

  2003cited by this paper

• No citing papers are available for this paper.